Amphastar Pharmaceuticals (AMPH) EBT (2016 - 2025)
Historic EBT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $21.5 million.
- Amphastar Pharmaceuticals' EBT fell 5488.33% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.1 million, marking a year-over-year decrease of 2863.99%. This contributed to the annual value of $195.2 million for FY2024, which is 728.66% up from last year.
- According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' EBT is $21.5 million, which was down 5488.33% from $39.3 million recorded in Q2 2025.
- Amphastar Pharmaceuticals' 5-year EBT high stood at $63.6 million for Q3 2023, and its period low was $5.1 million during Q1 2021.
- In the last 5 years, Amphastar Pharmaceuticals' EBT had a median value of $33.6 million in 2023 and averaged $35.8 million.
- As far as peak fluctuations go, Amphastar Pharmaceuticals' EBT surged by 104527.93% in 2021, and later crashed by 5488.33% in 2025.
- Quarter analysis of 5 years shows Amphastar Pharmaceuticals' EBT stood at $27.2 million in 2021, then skyrocketed by 93.0% to $52.4 million in 2022, then fell by 0.98% to $51.9 million in 2023, then decreased by 4.88% to $49.4 million in 2024, then plummeted by 56.43% to $21.5 million in 2025.
- Its EBT was $21.5 million in Q3 2025, compared to $39.3 million in Q2 2025 and $30.9 million in Q1 2025.